As of 30 Sep 2025, 84 institutional investors reported holding 10,315,270 shares of GALECTIN THERAPEUTICS INC - COM NEW (GALT).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 430,339 | $1,533,736 | +$180,546 | $4.16 | 13 |
| 2025 Q3 | 10,315,270 | $43,896,766 | -$59,992 | $4.24 | 84 |
| 2025 Q2 | 10,463,242 | $22,085,893 | +$1,798,907 | $2.11 | 84 |
| 2025 Q1 | 9,907,188 | $12,119,730 | -$167,177 | $1.22 | 88 |
| 2024 Q4 | 8,897,790 | $11,448,087 | -$37,211 | $1.29 | 91 |
| 2024 Q3 | 9,746,940 | $26,802,643 | +$624,662 | $2.75 | 84 |
| 2024 Q2 | 9,417,077 | $21,280,671 | +$4,010,407 | $2.26 | 71 |
| 2024 Q1 | 7,591,787 | $18,144,362 | +$1,189,286 | $2.39 | 58 |
| 2023 Q4 | 7,198,494 | $11,960,152 | -$3,133,058 | $1.66 | 65 |
| 2023 Q3 | 9,021,396 | $17,321,452 | +$3,461,993 | $1.92 | 57 |
| 2023 Q2 | 7,248,363 | $10,436,791 | +$114,237 | $1.44 | 57 |
| 2023 Q1 | 7,149,085 | $15,012,391 | +$220,031 | $2.10 | 55 |
| 2022 Q4 | 5,817,043 | $6,572,047 | +$182,097 | $1.13 | 55 |
| 2022 Q3 | 5,623,877 | $9,161,983 | -$200,081 | $1.63 | 50 |
| 2022 Q2 | 4,989,777 | $6,533,368 | -$574,540 | $1.31 | 51 |
| 2022 Q1 | 6,187,317 | $9,953,681 | -$321,739 | $1.61 | 51 |
| 2021 Q4 | 7,317,319 | $15,147,161 | -$496,898 | $2.07 | 50 |
| 2021 Q3 | 7,199,021 | $27,896,646 | -$2,183,678 | $3.88 | 66 |
| 2021 Q2 | 6,545,782 | $20,956,481 | -$4,999,225 | $3.20 | 69 |
| 2021 Q1 | 9,386,091 | $20,370,792 | -$1,721,147 | $2.17 | 67 |
| 2020 Q4 | 10,671,713 | $23,771,956 | +$477,683 | $2.24 | 72 |
| 2020 Q3 | 9,980,249 | $26,657,365 | -$295,234 | $2.67 | 63 |
| 2020 Q2 | 8,210,004 | $25,106,126 | +$905,753 | $3.06 | 70 |
| 2020 Q1 | 9,675,862 | $18,960,521 | -$1,078,763 | $1.96 | 71 |
| 2019 Q4 | 10,032,218 | $28,694,662 | +$1,838,375 | $2.86 | 73 |
| 2019 Q3 | 9,374,780 | $34,397,974 | +$3,085,518 | $3.67 | 74 |
| 2019 Q2 | 8,481,799 | $35,182,714 | +$4,360,500 | $4.15 | 71 |
| 2019 Q1 | 6,607,317 | $33,760,204 | +$9,063,343 | $5.11 | 61 |
| 2018 Q4 | 5,057,371 | $17,374,137 | -$2,419,279 | $3.43 | 56 |
| 2018 Q3 | 6,014,860 | $35,757,691 | +$1,920,661 | $6.01 | 59 |
| 2018 Q2 | 5,574,605 | $35,451,254 | +$4,179,619 | $6.36 | 65 |
| 2018 Q1 | 4,958,803 | $23,498,190 | +$6,152,061 | $4.74 | 55 |
| 2017 Q4 | 3,732,462 | $12,473,134 | -$432,872 | $3.34 | 45 |
| 2017 Q3 | 3,785,199 | $8,075,086 | +$14,345 | $2.13 | 43 |
| 2017 Q2 | 3,974,231 | $9,770,000 | +$859,060 | $2.46 | 46 |
| 2017 Q1 | 3,533,635 | $8,127,000 | +$1,927,125 | $2.30 | 37 |
| 2016 Q4 | 2,841,376 | $2,780,000 | -$227,400 | $0.98 | 33 |
| 2016 Q3 | 3,025,343 | $3,418,775 | -$601,055 | $1.13 | 39 |
| 2016 Q2 | 3,485,735 | $5,121,675 | -$569,634 | $1.47 | 42 |
| 2016 Q1 | 3,475,011 | $4,964,000 | -$242,726 | $1.43 | 39 |
| 2015 Q4 | 3,554,061 | $5,825,000 | +$1,251,091 | $1.64 | 45 |
| 2015 Q3 | 2,581,980 | $6,040,000 | -$1,403,373 | $2.34 | 38 |
| 2015 Q2 | 3,143,052 | $8,576,596 | -$2,044,467 | $2.73 | 51 |
| 2015 Q1 | 4,048,478 | $13,570,527 | +$949,193 | $3.35 | 56 |
| 2014 Q4 | 3,748,212 | $13,000,775 | -$3,076,358 | $3.47 | 57 |
| 2014 Q3 | 4,279,131 | $21,526,740 | -$4,778,203 | $5.03 | 60 |
| 2014 Q2 | 4,244,719 | $58,616,737 | +$9,156,703 | $13.81 | 62 |
| 2014 Q1 | 3,468,577 | $53,101,000 | +$31,887,250 | $15.31 | 49 |